The anti-VEGF abicipar pegol was similarly efficacious in treating neovascular age-related macular degeneration as ranibizumab, meeting the primary endpoint of non-inferiority in two phase 3 clinical trials, Allergan and Molecular Partners announced in a press release.
After six or eight injections, abicipar, a DARPin molecule, demonstrated similar efficacy as 13 injections of Lucentis (ranibizumab, Genentech) in both the CEDAR and SEQUOIA trials after the first year. Both trials were multicenter, randomized studies that evaluated the efficacy and safety of abicipar in patients with
Uncategorized